nanoPET Tracers

Novel nanoparticulate tracers for clinical positron emission tomography (PET)

As an addition to the pre‐clinical portfolio, nanoPET plans to clinically develop its patented technology: Inorganic nanoparticular tracers for cell‐ and molecular‐specific positron emission tomography (PET).

nanoPET Pharma has recently been awarded 75 milion EUR in funding by the German Federal Ministry of Education and Research (BMBF) to boost pre‐clinical development of the myocarditis tracer. Click here for details (German).

Please contact Dr. Andreas Briel for further information or use the contact form.